SOURCE: Medistem Laboratories

February 21, 2007 08:05 ET

Paradigm-Shifting Paper Published

Publication of Article by Medistem Scientists Supports Cord Blood Transplants in Absence of Immune Suppression

SCOTTSDALE, AZ -- (MARKET WIRE) -- February 21, 2007 -- Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) announced today the publication of a peer-reviewed paper which appears to be the first scientific review of the rationale for the practical use of umbilical cord stem cells without the use of immune suppression. Using donor stem cells without immune suppression opens the door to an increased number of potential medical applications including Medistem's Angiostem platform, which is currently under development for U.S. commercialization.

"The cord blood banking industry has exploded in the past several years with companies such as Viacell's Viacord and CryoCell storing increasing numbers of cord blood samples. However, the current uses of cord blood are limited primarily to indications such as oncology and very rare genetic disorders," said Neil Riordan Ph.D, President and CEO of Medistem. "The acceptance of our ideas by the scientific community in the form of a peer reviewed publication adds credence to our work aimed at expanding the use of cord blood into conditions that are currently limited by the need for immune suppression."

The publication, titled "Cord Blood for Regenerative Medicine: Do We Need Immune Suppression?" was published in the Journal of Translational Medicine and was granted "Highly Accessed" status based on scientific reader interest. It is freely available on the Journal's Website at

Thomas Ichim, Medistem's Chief of Scientific Development, commented, "Having intellectual property covering the various ideas presented in this paper positions Medistem to develop a wide array of therapeutic candidates based on cord blood manipulation." He further commented, "We have begun the process of creating U.S. therapeutic candidates by focusing on our Angiostem product, which aims to restore circulation in patients with critical limb ischemia through administration of manipulated cord blood cells. With companies such as Osiris Therapeutics having already demonstrated clinical safety of various allogeneic stem cell approaches, we feel that through the application of Medistem's proprietary methodologies it is feasible to believe that such allogeneic stem cell therapy approaches may soon be extended to cord blood derived stem cells."

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients while seeking to commercialize products in the U.S. market. Clinic treatments use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for the treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:

    Medistem Laboratories, Inc.
    Chris McGuinn